Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Neurological Biomarkers Market, by Type
1.4.2 Global Neurological Biomarkers Market, by Application
1.4.3 Global Neurological Biomarkers Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Neurological Biomarkers Market by Type
3.1 Global Proteomic Market by Region
3.2 Global Genomic Market by Region
3.3 Global Metabolomic Market by Region
3.4 Global Others Market by Region
Chapter 4. Global Neurological Biomarkers Market by Application
4.1 Global Alzheimer's Disease Market by Region
4.2 Global Parkinson’s Disease Market by Region
4.3 Global Multiple Sclerosis Market by Region
Chapter 5. Global Neurological Biomarkers Market by Region
5.1 North America Neurological Biomarkers Market
5.1.1 North America Neurological Biomarkers Market by Type
5.1.1.1 North America Proteomic Market by Country
5.1.1.2 North America Genomic Market by Country
5.1.1.3 North America Metabolomic Market by Country
5.1.1.4 North America Others Market by Country
5.1.2 North America Neurological Biomarkers Market by Application
5.1.2.1 North America Alzheimer's Disease Market by Country
5.1.2.2 North America Parkinson’s Disease Market by Country
5.1.2.3 North America Multiple Sclerosis Market by Country
5.1.3 North America Neurological Biomarkers Market by Country
5.1.3.1 US Neurological Biomarkers Market
5.1.3.1.1 US Neurological Biomarkers Market by Type
5.1.3.1.2 US Neurological Biomarkers Market by Application
5.1.3.2 Canada Neurological Biomarkers Market
5.1.3.2.1 Canada Neurological Biomarkers Market by Type
5.1.3.2.2 Canada Neurological Biomarkers Market by Application
5.1.3.3 Mexico Neurological Biomarkers Market
5.1.3.3.1 Mexico Neurological Biomarkers Market by Type
5.1.3.3.2 Mexico Neurological Biomarkers Market by Application
5.1.3.4 Rest of North America Neurological Biomarkers Market
5.1.3.4.1 Rest of North America Neurological Biomarkers Market by Type
5.1.3.4.2 Rest of North America Neurological Biomarkers Market by Application
5.2 Europe Neurological Biomarkers Market
5.2.1 Europe Neurological Biomarkers Market by Type
5.2.1.1 Europe Proteomic Market by Country
5.2.1.2 Europe Genomic Market by Country
5.2.1.3 Europe Metabolomic Market by Country
5.2.1.4 Europe Others Market by Country
5.2.2 Europe Neurological Biomarkers Market by Application
5.2.2.1 Europe Alzheimer's Disease Market by Country
5.2.2.2 Europe Parkinson’s Disease Market by Country
5.2.2.3 Europe Multiple Sclerosis Market by Country
5.2.3 Europe Neurological Biomarkers Market by Country
5.2.3.1 Germany Neurological Biomarkers Market
5.2.3.1.1 Germany Neurological Biomarkers Market by Type
5.2.3.1.2 Germany Neurological Biomarkers Market by Application
5.2.3.2 UK Neurological Biomarkers Market
5.2.3.2.1 UK Neurological Biomarkers Market by Type
5.2.3.2.2 UK Neurological Biomarkers Market by Application
5.2.3.3 France Neurological Biomarkers Market
5.2.3.3.1 France Neurological Biomarkers Market by Type
5.2.3.3.2 France Neurological Biomarkers Market by Application
5.2.3.4 Russia Neurological Biomarkers Market
5.2.3.4.1 Russia Neurological Biomarkers Market by Type
5.2.3.4.2 Russia Neurological Biomarkers Market by Application
5.2.3.5 Spain Neurological Biomarkers Market
5.2.3.5.1 Spain Neurological Biomarkers Market by Type
5.2.3.5.2 Spain Neurological Biomarkers Market by Application
5.2.3.6 Italy Neurological Biomarkers Market
5.2.3.6.1 Italy Neurological Biomarkers Market by Type
5.2.3.6.2 Italy Neurological Biomarkers Market by Application
5.2.3.7 Rest of Europe Neurological Biomarkers Market
5.2.3.7.1 Rest of Europe Neurological Biomarkers Market by Type
5.2.3.7.2 Rest of Europe Neurological Biomarkers Market by Application
5.3 Asia Pacific Neurological Biomarkers Market
5.3.1 Asia Pacific Neurological Biomarkers Market by Type
5.3.1.1 Asia Pacific Proteomic Market by Country
5.3.1.2 Asia Pacific Genomic Market by Country
5.3.1.3 Asia Pacific Metabolomic Market by Country
5.3.1.4 Asia Pacific Others Market by Country
5.3.2 Asia Pacific Neurological Biomarkers Market by Application
5.3.2.1 Asia Pacific Alzheimer's Disease Market by Country
5.3.2.2 Asia Pacific Parkinson’s Disease Market by Country
5.3.2.3 Asia Pacific Multiple Sclerosis Market by Country
5.3.3 Asia Pacific Neurological Biomarkers Market by Country
5.3.3.1 China Neurological Biomarkers Market
5.3.3.1.1 China Neurological Biomarkers Market by Type
5.3.3.1.2 China Neurological Biomarkers Market by Application
5.3.3.2 Japan Neurological Biomarkers Market
5.3.3.2.1 Japan Neurological Biomarkers Market by Type
5.3.3.2.2 Japan Neurological Biomarkers Market by Application
5.3.3.3 India Neurological Biomarkers Market
5.3.3.3.1 India Neurological Biomarkers Market by Type
5.3.3.3.2 India Neurological Biomarkers Market by Application
5.3.3.4 Australia Neurological Biomarkers Market
5.3.3.4.1 Australia Neurological Biomarkers Market by Type
5.3.3.4.2 Australia Neurological Biomarkers Market by Application
5.3.3.5 South Korea Neurological Biomarkers Market
5.3.3.5.1 South Korea Neurological Biomarkers Market by Type
5.3.3.5.2 South Korea Neurological Biomarkers Market by Application
5.3.3.6 Singapore Neurological Biomarkers Market
5.3.3.6.1 Singapore Neurological Biomarkers Market by Type
5.3.3.6.2 Singapore Neurological Biomarkers Market by Application
5.3.3.7 Rest of Asia Pacific Neurological Biomarkers Market
5.3.3.7.1 Rest of Asia Pacific Neurological Biomarkers Market by Type
5.3.3.7.2 Rest of Asia Pacific Neurological Biomarkers Market by Application
5.4 LAMEA Neurological Biomarkers Market
5.4.1 LAMEA Neurological Biomarkers Market by Type
5.4.1.1 LAMEA Proteomic Market by Country
5.4.1.2 LAMEA Genomic Market by Country
5.4.1.3 LAMEA Metabolomic Market by Country
5.4.1.4 LAMEA Others Market by Country
5.4.2 LAMEA Neurological Biomarkers Market by Application
5.4.2.1 LAMEA Alzheimer's Disease Market by Country
5.4.2.2 LAMEA Parkinson’s Disease Market by Country
5.4.2.3 LAMEA Multiple Sclerosis Market by Country
5.4.3 LAMEA Neurological Biomarkers Market by Country
5.4.3.1 Brazil Neurological Biomarkers Market
5.4.3.1.1 Brazil Neurological Biomarkers Market by Type
5.4.3.1.2 Brazil Neurological Biomarkers Market by Application
5.4.3.2 Argentina Neurological Biomarkers Market
5.4.3.2.1 Argentina Neurological Biomarkers Market by Type
5.4.3.2.2 Argentina Neurological Biomarkers Market by Application
5.4.3.3 UAE Neurological Biomarkers Market
5.4.3.3.1 UAE Neurological Biomarkers Market by Type
5.4.3.3.2 UAE Neurological Biomarkers Market by Application
5.4.3.4 Saudi Arabia Neurological Biomarkers Market
5.4.3.4.1 Saudi Arabia Neurological Biomarkers Market by Type
5.4.3.4.2 Saudi Arabia Neurological Biomarkers Market by Application
5.4.3.5 South Africa Neurological Biomarkers Market
5.4.3.5.1 South Africa Neurological Biomarkers Market by Type
5.4.3.5.2 South Africa Neurological Biomarkers Market by Application
5.4.3.6 Nigeria Neurological Biomarkers Market
5.4.3.6.1 Nigeria Neurological Biomarkers Market by Type
5.4.3.6.2 Nigeria Neurological Biomarkers Market by Application
5.4.3.7 Rest of LAMEA Neurological Biomarkers Market
5.4.3.7.1 Rest of LAMEA Neurological Biomarkers Market by Type
5.4.3.7.2 Rest of LAMEA Neurological Biomarkers Market by Application
Chapter 6. Company Profiles
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Bio-Rad laboratories, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expenses
6.3 Merck Group
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 PerkinElmer, Inc.
6.4.1 Company Overview
6.4.1 Financial Analysis
6.4.2 Segmental and Regional Analysis
6.4.3 Research & Development Expense
6.5 Shimadzu Corporation
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.6 Thermo Fisher Scientific, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 BioMérieux S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expenses
6.8 Myriad Genetics, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental Analysis
6.8.4 Research & Development Expenses
6.9 Quanterix Corporation
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.10. Neuro-Bio Ltd.
6.10.1 Company Overview
Unique Offerings 
